OTCQB: VYCO

CORPORATE PROFILE

DECEMBER 2016

Medical Device Innovator with Two "Game Changing" Product Lines that are FDA-Cleared

Key Stats *(Sources: Capital IQ, SEC filings, company)*

Stock Price (close) *(12/3/2016)*	*$0.38*
52 Week Low/High	*$0.21-$1.07*
Avg. Daily Vol. *(3 mo.)*	*5,100*
Shares Outstanding	*11.2M*
Free Float *(est.)*	*59%*
Insider Holdings[1]	*~41%*
Institutional Holdings	*<1%*
Market Capitalization	*$4.3M*
Enterprise Value	*$4.7M*
Total Revenue *(ttm)*[2]	*$1.4M*
Cash Op. Exp. *(ttm)*[2]	*$1.9M*
Cash EBITDA Loss *(ttm)*[2]	*$1.7M*
Net Loss *(ttm)*[2]	*$(0.15)M*
EV/Revenue *(ttm)*[2]	*3.4X*
Total Assets *(mrq)*	*$1.5M*
Total Net Debt *(mrq)*	*$0.5M*
Employees	*13*
Founded	*2005*

Vycor Medical Global Offices

Corporate Headquarters
6401 Congress Avenue Suite 140
Boca Raton, FL 33487

European Sales Offices
Klausenerstr. 12
39112 Magdeburg, Germany

214 Union St., Aberdeen, AB10 1TL
Scotland, United Kingdom

Company Contacts

Peter Zachariou, CEO
David Cantor, President
Adrian Liddell, Chairman & CFO
Tel: 561.558.2020
www.vycormedical.com
investorinfo@vycormedical.com

About Vycor Medical

Vycor Medical provides minimal or non-invasive neurosurgical and neurotherapeutic solutions

- Technologies validated by numerous independent practitioners and published clinical studies
- IP portfolio of 57 patents and 13 pending

Products

- **NovaVision Visual Restoration Therapy (VRT)**: Only FDA-cleared therapy for restoration of vision loss as the result of stroke or brain damage
- **NeuroEyeCoach:** helps patient compensate for vision disorders as a result of stroke or brain damage (FDA registered)
- **ViewSite Brain Access System (VBAS):** a revolutionary, field-proven, minimally invasive neurosurgical device for accessing tumors and other lesions within the brain
- **High gross margin:** 80%+

Large Addressable Markets

- **NovaVision:** 30% or 2.4 million stroke survivors in the U.S. suffer from a vision disorder, creating a ~$4 billion US/Europe market & ~$13 billion globally[4]
- **VBAS:** $700 million globally[4]

2015 News Highlights

Oct: rigorous study published on NeuroEyeCoach, concluding the therapy can be viewed as the first evidence-based, vision-specific, **clinical gold standard** registered medical device accessible to patients at home or in clinical settings

Mar, Jul, Oct: 3 new clinical papers published by surgeons from hospitals in the US, Italy and Japan respectively, adding to the large body of clinical support for VBAS. There have now been a total of 16 papers, 10 in 2015 and 2016 alone, evidencing VBAS' clinical superiority

Mar: launched its VBASmini, two new smaller models of its TC range. The VBASmini is the largest clear device available that can fit through an 11mm burr hole yet still provide a large enough working channel to be useful in neurosurgery

ViewSite™ Brain Access System

ViewSite Brain Access System (VBAS) is a revolutionary neurosurgical device used to retract & gain access to targets within the brain.

NovaVision



NovaVision's suite of complementary therapies helps patients with vision disorders resulting from stroke or brain injury.



$13 Billion NovaVision Global Market Opportunity[4]



1. Insiders include directors and Fountainhead Capital Management 2.. Based on twelve months to September 30, 2016 and balance sheet at that date. 4. Company estimate. **Disclaimer:** This document is for informational purposes only; it should not be construed as an offer to buy or sell securities. No guarantee is made as to accuracy, completeness, or timeliness of information provided. This document includes "forward looking statements" as defined by the Securities & Exchange Commission (SEC). All statements, other than historical facts, that address activities, events or developments that will or may occur in the future are considered forward-looking and are subject to a number of assumptions, risks and uncertainties. Investors are cautioned any such statements are not guarantees of future performance and actual results may differ materially due to of many factors. For further information about forward-looking statements, please see the company's most recent 10-K, 10-Q and other filings with the SEC. Content of this document is © Vycor Medical, Inc. 2016. mrq = most recent quarter, ttm = trailing twelve months.